Ophthalmic Images

Central Retinal Artery Revascularization Promptly After Tenecteplase

Alexander T. Vo, DO; Bobeck S. Modjtahedi, MD; Navdeep S. Sangha, MD




Figure. Fundus photograph of the right eye at presentation (A) and 60 minutes (B) after administration of tenecteplase. A, There is a cherry-red spot in the macula, retinal arteriolar boxcarring (black arrowheads), and likely an intra-arterial linear embolus within the inferior retinal artery at the disc (white arrowhead). B, There is resolution of the retinal whitening, retinal arteriolar boxcarring, and retinal embolus (white arrowhead) with minimal residual retinal arterial whitening temporally and inferiorly (black arrowheads).

A70-year-old male presented to the emergency department with acute onset of painless monocular vision loss of his right eye. Visual acuity on presentation was light perception. Fundus photographs taken in the emergency department demonstrated diffuse inner reti-



CME at jamacmelookup.com

nal whitening, a macular cherryred spot, segmental irregularities of the retinal arterioles (also known as *boxcarring*), and an in-

tra-arterial embolus characteristic of a central retinal artery occlusion (CRAO) (Figure, A). He received intravenous tenecteplase,

0.25 mg/kg, 149 minutes after onset of persistent vision loss, with improvement in vision 15 minutes thereafter. Repeat fundus photographs taken 60 minutes after administration of tenecteplase demonstrated reperfusion of the retinal arteries (Figure, B). At ophthalmology clinic follow-up 3 weeks later, his visual acuity was 20/150 OD. This case provides photographically documented retinal revascularization after intravenous thrombolytics and contributes to the growing body of literature that suggests that this therapeutic option may hold promise in the management of CRAO.¹⁻⁵

ARTICLE INFORMATION

Author Affiliations: Department of Neurology, Kaiser Permanente Los Angeles, Los Angeles, California (Vo, Sangha); Department of Research and Evaluation, Southern California Permanente Medical Group, Pasadena (Modjtahedi, Sangha); Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California (Modjtahedi, Sangha); Eye Monitoring Center, Kaiser Permanente Southern California, Baldwin Park (Modjtahedi).

Corresponding Author: Alexander T. Vo, DO, Department of Neurology, Kaiser Permanente Los Angeles, 1505 N Edgemont St, 5th Floor, Los Angeles, CA 90027 (alex.t.vo@kp.org).

Conflict of Interest Disclosures: Dr Modjtahedi reported receiving grants from Genentech and VoxelCloud outside the submitted work. No other disclosures were reported.

Additional Contributions: We thank the patient for granting permission to publish this information.

REFERENCES

- 1. Schrag M, Youn T, Schindler J, Kirshner H, Greer D. Intravenous fibrinolytic therapy in central retinal artery occlusion: a patient-level meta-analysis. *JAMA Neurol*. 2015;72(10):1148-1154. doi:10.1001/jamaneurol.2015.1578
- 2. Mac Grory B, Nackenoff A, Poli S, et al. Intravenous fibrinolysis for central retinal artery occlusion: a cohort study and updated patient-level meta-analysis. *Stroke*. 2020;51(7):2018-2025. doi: 10.1161/STROKEAHA.119.028743
- 3. Dumitrascu OM, Newman NJ, Biousse V. Thrombolysis for central retinal artery occlusion in 2020: time is vision! *J Neuroophthalmol*. 2020; 40(3):333-345. doi:10.1097/WNO. 00000000000000001027
- 4. Mac Grory B, Schrag M, Biousse V, et al; American Heart Association Stroke Council; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; and Council on Peripheral Vascular Disease. Management of central retinal artery occlusion: a scientific statement from the American Heart Association. *Stroke*. 2021;52 (6):e282-e294. doi:10.1161/STR. 000000000000000366
- 5. Kozner P, Eichenmann L, Ceska Burdova M, Pavlikova M, Hlozanek M, Dotrelova D. Long-term outcomes of intravenous fibrinolysis in central retinal artery occlusion. *Sci Rep.* 2023;13(1):20505. doi:10.1038/s41598-023-47987-9